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Objective, Design, Setting: This proof-of-concept study evaluated the performance of urine 
steroid metabolomics as a tool for postoperative recurrence detection after microscopically 
complete (R0) resection of ACC.
Patients and Methods: 135 patients from 14 clinical centers provided postoperative urine 
samples, which were analyzed by gas chromatography–mass spectrometry. We assessed the 
utility of these urine steroid profiles in detecting ACC recurrence, either when interpreted 
by expert clinicians or when analyzed by random forest, a machine learning-based classifier. 
Radiological recurrence detection served as the reference standard.
Results: Imaging detected recurrent disease in 42 of 135 patients; 32 had provided pre- 
and post-recurrence urine samples. 39 patients remained disease-free for ≥3 years. The 
urine “steroid fingerprint” at recurrence resembled that observed before R0 resection 
in the majority of cases. Review of longitudinally collected urine steroid profiles by 3 
blinded experts detected recurrence by the time of radiological diagnosis in 50% to 72% 
of cases, improving to 69% to 92%, if a preoperative urine steroid result was available. 
Recurrence detection by steroid profiling preceded detection by imaging by more than 
2 months in 22% to 39% of patients. Specificities varied considerably, ranging from 61% 
to 97%. The computational classifier detected ACC recurrence with superior accuracy 
(sensitivity = specificity = 81%).
Conclusion: Urine steroid metabolomics is a promising tool for postoperative recurrence 
detection in ACC; availability of a preoperative urine considerably improves the ability to detect 
ACC recurrence. (J Clin Endocrinol Metab 105: 1–12, 2020)
Key Words:  adrenocortical carcinoma, ACC, steroid metabolomics, mass spectrometry, machine 
learning, recurrence detection
Adrenocortical carcinoma (ACC) is a rare and ag-gressive malignancy (1, 2). Disease recurrence rates 
are high, even in patients with microscopically complete 
(R0) resection (3, 4). Therefore, vigilant surveillance of 
all operated patients by regular cross-sectional imaging 
for several years is essential to facilitate early inter-
vention in case of recurrence (5–7). Although the op-
timal surveillance protocol has yet to be established, a 
common approach involves 3-month CT scans (thorax, 
abdomen, pelvis) in the first 2 postoperative years, 
6-month CT scans in the next 3 years and, thereafter, 
annual scans until 10 years postoperatively (8). This is 
associated with considerable costs, repeated radiation 
exposure, and frequent diagnostic ambiguity in early 
stages of recurrent/metastatic disease (9). Early detec-
tion of disease recurrence is important, as it may allow 
radical revision surgery in cases of limited metastatic 
disease volume or timely initiation of cytotoxic chemo-
therapy, potentially improving survival (5, 7, 10–13). 
The number of metastatic sites at diagnosis of recurrent 
disease and time from surgery to detection of recurrence 
have been shown to be independent prognostic factors 
(10, 14).
Most ACCs are biochemically active, typically pre-
senting a steroidogenic pattern dominated by steroid 
precursor metabolites rather than end products of 
steroidogenesis (15). This pattern has been attrib-
uted to the relative dedifferentiation of malignant 
cells (15,   16). Most of these steroid precursors, 
which represent intermediate steps along the 3 major 
adrenocortical steroid biosynthetic pathways, are not 
measured by routine clinical biochemistry. Analysis 
of 24-hour urine collections by gas chromatography–
mass spectrometry (GC-MS), however, can identify 
and quantify the metabolites of the large majority of 
adrenal-derived steroids, providing a truly compre-
hensive steroid profiling tool (15). This allows the de-
tection of minute changes in steroidogenesis and the 
illumination of all intermediate steps that tend to be 
perturbed in the setting of adrenocortical malignancy. 
Recent retrospective studies revealed the capacity of 
urinary steroid profiling to distinguish ACC from be-
nign adrenal tumors. In 2011, our group analyzed 
steroid metabolite profiles in 24-hour collections from 
102 patients with benign adrenocortical adenomas 
and 56 patients with ACC by GC-MS (15). Machine 
learning–based analysis of the steroid data identified 
a distinct malignant steroid “fingerprint” for ACC 
and could differentiate benign from malignant ad-
renal tumors with a sensitivity and specificity of 90% 
(15). Using GC-MS, 95% of ACCs showed evidence 
of steroid excess, while routine biochemistry only in-
dicated steroid excess in 73% (15). Two subsequent 
retrospective studies also employing GC-MS produced 
similar results, albeit in smaller cohorts and without 
the use of machine learning analysis (16, 17).










roningen user on 09 M
arch 2020
In this study, we evaluated the diagnostic perform-
ance of urine steroid metabolomics, the combination 
of mass spectrometry-based steroid profiling and data 
analysis by machine learning-based algorithms, in the 
postoperative surveillance of ACC patients following 
microscopically complete (R0) tumor resection. We as-
sessed the performance of this approach in the detection 
of disease recurrence, also comparing direct interpret-
ation of steroid profiles by clinical experts to fully auto-
mated, machine learning–based analysis of the steroid 
metabolome.
Methods
Patients and clinical protocol
Serial postoperative 24-hour urine samples were col-
lected from patients with histologically confirmed ACC, who 
had undergone microscopically complete (R0) tumor re-
section in 14 clinical specialist referral centers participating 
in the European Network for the Study of Adrenal Tumors 
(ENS@T; www.ensat.org), with approval of local ethical re-
view boards and after obtaining written informed patient 
consent. Participating countries included the United Kingdom 
(Birmingham), Germany (Würzburg, Munich, Berlin), France 
(Paris), Italy (Florence, Turin), Greece (Athens), the Republic 
of Ireland (Dublin, Galway), Poland (Warsaw), Croatia 
(Zagreb), and Portugal (Coimbra, Lisbon). Urine samples 
were collected between 2007 and 2016. Inclusion criteria were 
defined as (i) histologically confirmed diagnosis of ACC, (ii) 
complete (R0) tumor resection, and (iii) provision of at least 1 
postoperative 24-hour urine sample when disease-free, that is, 
before any radiological evidence of disease recurrence (as as-
sessed by computed tomography [CT] thorax, abdomen, and 
pelvis) and within 2 years from surgery. Participating centers 
were prompted to provide urine samples every 3 months, but 
actual frequency of provided samples did not constitute an ex-
clusion criterion as long as at least 1 postoperative sample had 
been provided at a time with no evidence of disease recurrence 
on surveillance imaging.
ACC recurrence had to be confirmed by 1 of the following: 
(i) emergence of new lesions on cross-sectional imaging 
(CT, magnetic resonance imaging), which either enlarge on 
follow-up scans or regress in response to systemic antitumor 
therapy; (ii) emergence of enhancing lesions on positron emis-
sion tomography or positron emission tomography CT scans; 
or (iii) histological evidence of recurrent/metastatic ACC from 
percutaneous biopsy or revision surgery.
Biochemical analysis
Measurement of 24-hour urinary steroid metabolite ex-
cretion was carried out by GC-MS, as described in detail 
previously (15). In brief, free and conjugated steroids were 
extracted from 1 mL urine by solid-phase extraction. Steroid 
conjugates were enzymatically hydrolyzed, re-extracted, and 
chemically derivatized to form methyloxime trimethyl silyl 
ethers. GC-MS was carried out on an Agilent 5975 instrument 
operating in selected-ion-monitoring mode to achieve sensi-
tive and specific detection and quantification of 19 selected 
steroid metabolites (Table 1) comprising 8 of the 9 previously 
described “malignant steroid fingerprint” metabolites indica-
tive of ACC (15). We did not include glucocorticoid metab-
olites as these are uninterpretable in mitotane-treated ACC 
patients, who all receive high-dose glucocorticoid replacement 
Table 1. Urinary steroid metabolites quantified by gas chromatography–mass spectrometry and their 
corresponding steroids of origin
No Steroid Metabolite Metabolite of
Androgen and androgen precursor metabolites
1 Androsterone (An) Androstenedione, testosterone, 5α-dihydrotestosterone
2 Etiocholanolone (Et)a Androstenedione, testosterone
3 11β-hydroxyandrosterone (11β-OHAn) Androstenedione, 11β-hydroxyandrostenedione
4 Dehydroepiandrosterone (DHEA) DHEA, DHEAS
5 16α-hydroxy-DHEA (16α-DHEA) DHEA, DHEAS
6 5-pregnenetriol (5-PT)a 17-hydroxypregnenolone
7 5-pregnenediol (5-PD)a Pregnenolone
Mineralocorticoid and mineralocorticoid precursor metabolites




10 Tetraydrocorticosterone (THB) Corticosterone
11 5α-tetrahydrocorticosterone (5α-THB) Corticosterone
12 3α,5β-tetrahydroaldosterone (THALDO) Aldosterone
13 Tetrahydrodeoxycorticosterone (THDOC)a 11-deoxycorticosterone
Glucocorticoid precursor metabolites
14 Pregnanediol (PD)a Progesterone
15 3α,5α-17-hydroxypregnanolone (3α,5α-17HP) 17-hydroxyprogesterone
16 17-hydroxypregnanolone (17HP) 17-hydroxyprogesterone
17 Pregnanetriol (PT)a 17-hydroxyprogesterone
18 Pregnanetriolone (PTONE) 21-deoxycortisol
19 Tetrahydro-11-deoxycortisol (THS)a 11-deoxycortisol
These 19 steroids include 8 steroid metabolites previously described as components of the “malignant steroid fingerprint” diagnostic for adrenocortical 
carcinoma upon analysis of 24-hour urines from patients with benign and malignant adrenocortical masses (15).
a“Malignant” steroid metabolite.
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while also being subject to the strong induction of the cortisol-
metabolizing enzyme CYP3A4 by mitotane (18).
Clinical expert review of steroid profiles
Three clinical experts with extensive experience in adrenal 
disease (I.B., M.O.R., W.A.) were provided with longitudin-
ally collected postoperative urinary steroid profiles from pa-
tients who either (i) developed disease recurrence (“recurrence 
cohort”) or (ii) remained recurrence-free over a follow-up 
period of at least 3  years, which we considered our “recur-
rence negative” cohort, as the chances of ACC recurrence past 
this time-point are low (19). Provision of at least 1 sample at 
a “disease-free” state was an essential inclusion criterion for 
this study; therefore, all included recurred patients had pro-
vided at least 2 postoperative urine samples (one pre- and one 
post-recurrence). Similarly, we only included patients from 
the “recurrence-free” cohort who had provided at least 2 
postoperative urine samples for this study part. Preoperative 
steroid profiles were provided when available.
The 3 assessors were blinded to clinical and radiological 
information other than basic patient demographics (age, sex) 
and were only provided with a previously established steroid 
metabolite reference range derived from a healthy adult con-
trol cohort (age range 20–81 years; 77 women, 54 men). The 
clinical experts were asked to identify the first urine indicative 
of a recurrence (or state “no recurrence” in patients that they 
considered as non-recurred), taking into account differences 
of the steroid profiles to those observed in healthy controls 
and the previously observed “malignant steroid fingerprint” in 
patients with a primary ACC tumor in situ (15).
Recurrence detection by the clinical experts was considered 
successful only if based on interpretation of the steroid profile 
in a urine sample collected before or at the time of the first 
radiological detection of recurrent disease. This means that 
late biochemical detection in relation to imaging did not count 
as true positive for the purposes of sensitivity calculations.
Machine learning–based data analysis
Supervised machine learning was used to create an ap-
proach for automatic separation of recurrent from non-
recurrent patients (20). The machine learning algorithm was 
developed by presenting the results of the 19 steroid markers 
measured by GC-MS in a given 24-hour urine, and the corres-
ponding output, that is, a “yes” or “no” answer to the ques-
tion of whether an ACC recurrence had been radiologically 
detected at the time of urine collection. From these “training” 
examples, the algorithm learned to generalize by finding pat-
terns in the steroid data and use them to provide an output 
answer when the output is not known.
We used machine learning to approach 2 separate 2-class 
classification problems. First, we considered the differenti-
ation of all 215 urine samples collected in the 39 non-recurred 
patients from all 76 urine samples collected post-recurrence 
in the 32 recurred patients. Second, to test the ability of our 
approach for very early detection, we aimed to differentiate all 
non-recurred samples against the first urine sample collected 
in each recurrent patient at the time of first radiological detec-
tion of ACC recurrence (35 samples, as 3 of 32 patients had 
2 recurrences).
Random forests were used as machine learning classifier 
(21, 22). The random forest is a classification framework 
based on the concept of decision trees. It builds a forest of 
many decision trees to create a strong classifier that is re-
sistant to noise and overtraining. Another favorable property 
of random forests is that they give insight into the importance 
of features, which we exploited to inspect the contribution 
and relevance of each steroid metabolite in the classification 
problem. For all experiments, training the random forest pre-
diction models and validating them, we used Matlab 2015a, 
specifically, the TreeBagger class of Matlab (included in the 
Statistics and Machine Learning Toolbox) (Matlab documen-
tation, 2018). To estimate predictor importance, the parameter 
that controls computation of predictor importance was set to 
“on” (this parameter is called “oobvarimp” in Matlab 2015a). 
The number of decision trees used to obtain the results was 
128, which provided optimal trade-off between speed and per-
formance. Tenfold cross-validation was used to estimate the 
classifier’s predictive quality. To account for the differences in 
the number of samples between the healthy and the recurrence 
classes, the validation procedure was repeated 50 times for 
randomized splits of the data. In each run, the healthy class 
was randomly subsampled to make sure that both classes had 
an equal number of samples.
Statistical analysis
Data analysis and graphic representation was completed 
using GraphPad Prism Software Version 8.  Data are sum-
marized as median (interquartile range) values unless other-
wise stated. Sensitivities and specificities are accompanied by 
95% confidence intervals (95% CI), derived using the Wilson/
Brown method (23, 24).
Results
Patient characteristics
We recruited 135 patients (50 men, 85 women) 
who had undergone complete (R0) resection of a 
histologically confirmed ACC and provided at least one 
24-hour urine sample while considered disease-free ac-
cording to their most recent clinical and radiological 
assessment and no later than 2  years postoperatively 
(Fig. 1). Median age at diagnosis was 49 years (range 
18–80 years).
During a median follow-up period of 32  months 
(interquartile range 15–48 months), 42 of 135 patients 
(31%) developed disease recurrence; of these, 10 had 
to be excluded from the analysis as they had not pro-
vided 24-hour urines after the detection of recurrence. 
Of the cohort of patients who remained disease-free 
postoperatively, 39 were clinically and radiologically 
followed for more than 3 years; as ACC recurrence pre-
senting beyond that time frame is rare (19), we defined 
those 39 patients as the “recurrence-free” cohort for the 
purposes of this study. Relevant clinical details of both 
cohorts are summarized in Table 2. The remaining 54 
patients without radiological evidence of recurrence but 
postoperative follow-up <3  years were excluded from 
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further analysis, as they were still at high risk of po-
tentially harboring minimal recurrent disease which had 
yet to manifest radiologically.
The 39 patients of the “recurrence-free” cohort pro-
vided a median of 4 (range 1–24) postoperative 24-hour 
urine samples. In the “recurrence” cohort, the patients 
collected a median of 5 (range 2–35) postoperative 
24-hour urine samples; 13 of the 32 patients had 
also collected a preoperative 24-hour urine sample, 
facilitating the comparison of steroid profiles observed 
at diagnosis of the primary tumor and at detection of 
ACC recurrence. All samples provided by the recurred 
patients are depicted in Fig. 2A, plotted against time 
after surgery. Single-organ involvement at recurrence 
detection was diagnosed in 26 of the 32 recurred pa-
tients; the remaining 6 had disease affecting more than 
1 organ (Table 2). We classified 15 of the 32 recurrences 
as “high volume” at the time of the first abnormal im-
aging, defined as at least 1 solid-organ lesion ≥1 cm, and 
12 as “low volume”; 5 were indeterminate due to in-
complete imaging information.Figure 1. Study recruitment flow chart.
Table 2. Demographic and clinical characteristics
Recurred patients (n = 32) Recurrence-free patients (n = 39)





52 (22–80) 56 (24–75)
Male patients n (%) 7 (22%) 17 (44%)
Primary tumor size (mm) 
median (IQR)
92 (70–118) 80 (66–140)
Evidence of biochemical hormone excess on routine 
biochemistry N/total N (%)
23/31 (74%) 16/33 (48%)
Type of hormone excess on routine biochemistry (n) Glucocorticoids (GC) only: 6 
Androgens only: 2 
Mineralocorticoids (MC) only: 0 
Precursor steroids only: 0 
GC + Androgens: 12 
MC + GC or Androgens: 3
GC only: 5 
Androgens only: 3 
MC only: 1 
Precursor steroids only: 1 
GC +Androgens: 4 
MC + GCs or Androgens: 2
Clinically overt Cushing’s syndrome  n/total N (%) 16/31  (52%) 5/38 (13%)
Histology primary tumor: Ki67 (%) median (IQR) 10 (7–26) 8 (5–15)
Histology primary tumor: Weiss score (0–9) median 
(IQR)
5 (4–7) 5 (3–7)
Adjuvant mitotane treatment: n (%) 20 (63%) 27 (69%)
Duration of follow up (months) median (IQR) 27 (18–44) 51 (41–65) 
Time to recurrence, (months) median (IQR) 15 (10–25) N/A
Maximum recurrent lesion size (mm) median (range) 11 (3–45) N/A
Number of organs involved in recurrence 1 (n = 27); 2 (n = 6); 3 (n = 3) N/A
Location of recurrences Lung (n = 22);  
Liver (n = 10); 
Lymph nodes (n = 5); 
Local recurrence (n = 4); 
Bone, spleen, omentum, pleura 
(each n = 1)
N/A
Demographics and clinical characteristics of the “recurrence” cohort of patients with disease recurrence and at least one post-recurrence urine 
(n = 32) and the “recurrence-free” cohort (patients disease-free after ≥3 years of follow-up; n = 39). Where data are not available for the full cohort, 
number of patients with available data is provided as denominator. 
Abbreviations: IQR, interquartile range; N, number; N/A, not applicable.
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Longitudinal urine steroid profiling
We hypothesized that the development of radiologic-
ally detectable recurrent or metastatic disease would be 
heralded by an increase in one or more adrenal steroid 
metabolites excreted in 24-hour urine. Such changes 
were indeed observed; indicative example cases are 
shown in heat-map format in Fig. 2B.
An important question here was whether the “malig-
nant steroid fingerprint” observed at baseline (ie, in the 
preoperative urine at the time of first diagnosis of ACC) 
represents an inherent characteristic of the individual 
ACC that is largely preserved upon disease recurrence. We 
found that this was indeed the case, with re-emergence 
of steroid metabolites at recurrence mostly identical 
to those found increased at baseline in the vast ma-
jority of patients (Fig. 3A). The overall 6 most increased 
steroids comprised the 11-deoxycortisol metabolite, 
tetrahydro-11-deoxycortisol (THS); the 11-deoxycortico-
sterone metabolite, tetrahydrodeoxycorticosterone; the 
pregnenolone and 17-hydroxypregnenolone  metabolites, 
5-pregnenediol and 5-pregnenetriol; and the progesterone 
and 17-hydroxyprogesterone  metabolites, pregnanediol 
and pregnanetriol (Fig. 3B). The magnitude of steroid 
marker elevation, however, was substantially smaller upon 
disease recurrence than in primary ACCs (Table 3), as ex-
pected in view of the major differences in disease volume 
between primary tumor and ACC recurrence (median 
maximum diameter 92 vs. 11 mm, respectively; Table 2).
Figure 2. (A) All longitudinal urine samples collected from patients who developed disease recurrence, plotted against time from surgery. Blue 
dots represent postoperative samples collected while the patient was considered disease-free according to their most recent clinical and radiological 
evaluation. Red dots represent samples collected after the first radiological manifestation of recurrent disease and before any second curative 
therapy. Purple dots represent samples that were collected preoperatively. (B) Heat-map visualization of longitudinal urinary steroid profile results 
in 5 representative patients who developed recurrent disease during follow-up. Arrows indicate the time of the first radiological manifestation of 
recurrent disease (Rec) and surgery for recurrence (Sx). Steroid numbers correspond to steroid metabolites as tabulated in Table 1.
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Expert clinician assessment of steroid profiling 
results
To evaluate the extent to which incipient steroid 
profile changes can facilitate diagnosis of recurrent 
disease, we asked 3 expert endocrinologists to retro-
spectively review longitudinal series of urinary steroid 
profiles individually derived from the “recurrence” and 
“recurrence-free” patient cohorts. The 3 expert clin-
icians were able to correctly identify recurrent disease 
by the time of the first post-recurrence sample (defined 
by reference to the first abnormal surveillance scan) with 
sensitivities of 66% (95% CI 48–80%), 53% (95% CI 
36–69%), and 75% (95% CI 58–87%) (clinicians 1, 
2, and 3, respectively). This improved substantially for 
the subgroup of patients who had provided preopera-
tive urine samples (n = 13) to 85% (95% CI 58–97%), 
69% (95% CI 42–87%) and 92% (95% CI 67–100%), 
respectively (Fig. 4A). Of note, 8 of the 13 assessed re-
currences in these patients were unanimously detected 
by all 3 reviewing clinicians. Absence of a preoperative 
sample curtailed diagnostic sensitivities to 53% (95% 
CI 32–73%), 42% (95% CI 23–64%), and 63% (95% 
CI 41–81%), respectively.
The diagnostic performance of the steroid profile re-
view was not altered by adjuvant mitotane treatment 
(Fig. 4B). Whether the tumor was found to be hormo-
nally active or not at baseline (on clinical biochemistry) 
also did not appear to affect the diagnostic performance 
of the urine steroid metabolome on recurrence (data not 
shown).
The proportion of non-recurred patients in whom 
recurrences were incorrectly detected by reviewing clin-
icians varied considerably across the assessors (false 
positive rates 23% [95% CI 11–39%], 3% [95% CI 
0–16%], and 39% [95% CI 24–56%] for clinicians 1, 2 
and 3, respectively; Fig. 4C). The effect of the availability 
of a preoperative urine sample on the specificity of detec-
tion could not be meaningfully assessed as only 5 non-
recurred patients had provided a preoperative sample.
Tumor volume at the time of first abnormal sur-
veillance imaging was a second clinical factor, which 
showed a tendency toward affecting clinician ability to 
detect recurrence (high-volume recurrence: sensitivities 
67% [95% CI 42–85%], 53% [95% CI 30–75%] and 
87% [95% CI 62–98%]; low-volume recurrence: 50% 
[95% CI 25–75%], 42% [95% CI 19–68%] and 58% 
[95% CI 32–81%] for clinicians 1–3, respectively).
Figure 3. Comparison of preoperative (baseline) and post-recurrence 
samples (13 patients with a total of 15 recurrences). (A) Overlap 
between baseline urine steroid profile and the profile of the first post-
recurrence sample provided by the same patient, when considering 
the 6 most elevated steroid metabolites in each sample. Steroid values 
were normalized to the upper limit of the reference range of the 
corresponding steroid metabolite in sex-matched healthy controls. (B) 
Frequency of inclusion of each steroid metabolite in the “top 6” most 
elevated steroid biomarkers. The presented panel consists of the 8 
steroid biomarkers previously described as part of the “malignant steroid 
fingerprint” diagnostic for adrenocortical carcinoma (15).
Table 3. Quantitation of the increases in the eight 
urine steroid metabolites previously described 
as part of the “malignant steroid fingerprint” 











THS 6.57 (0.83–41.2) 1.54 (0.35–14.50)
5-PD 3.80 (0.79–39.4) 0.43 (0.08–4.00)
PD 2.93 (0.51–8.80) 0.16 (0.03–1.10)
PT 1.70 (0.51–10.50) 0.22 (0.08–1.00)
5-PT 1.69 (0.53–20.00) 0.17 (0.04–4.40)
THDOC 1.39 (0.15–2.90) 0.21 (0.11–1.50)
Et 1.19 (0.12–3.30) 0.09 (0.02–1.00)
5α-THA 0.47 (0.10–1.00) 0.33 (0.09–0.51)
Steroid metabolites selected with reference to (15). Expressed as fold 
change in comparison to the upper limit of normal (ULN) referring to a 
healthy adult control cohort. We compared steroid excretion in the pre-
operative samples collected with the primary tumor in situ to the first 
urine samples collected after radiological recurrence detection ( = 1st 
post-recurrence sample) in the 13 patients with ACC recurrence who 
provided both pre- and postoperative urine samples.
Abbreviations: THS, tetrahydro-11-deoxycortisol; 5-PD, 5-pregnenediol; 
PD, pregnanediol; PT, pregnanetriol; 5-PT, 5-pregnenetriol; THDOC, 
tetrahydrodeoxycorticosterone; Etio, etiocholanolone; 5α-THA, 
5α-tetrahydro-11-dehydrocorticosterone.
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Of note, a considerable proportion of correct re-
currence detections (ranging from 22%–39% for 
the 3 experts) were made based on urine collections 
that predated the first radiological evidence of re-
currence by more than 2  months (Fig. 4D). Only a 
small number of recurrences were detected later by 
urine steroid profile interpretation than radiological 
detection. If late detections were accepted as posi-
tive, the overall sensitivities of the clinicians would 
improve to 75% (95% CI 58–87%), 56% (95% CI 
39–72%), and 81% (95% CI 65–91%) for clinicians 
1–3, respectively.
Computational analysis of steroid data
Machine learning-based analysis of the urine steroid 
profile data by random forests were able to distinguish 
post-recurrence urine samples (n = 76) provided by the 
32 recurred patients from postoperative urine samples 
(n = 215) provided by the 39 non-recurred patients with 
high accuracy (85%; area under the receiver operating 
characteristic curve (AUROC) 0.89, 95% CI 0.86–0.91; 
sensitivity = specificity = 81%) (Fig. 5A).
When considering only the first post-recurrence urine 
sample from each patient in the “recurrence” cohort, the 
accuracy of random forest classification was lower at 
75% (AUROC 0.80, 95% CI 0.75–0.85) (Fig. 5A), with 
the urine of 18 of 32 patients correctly classified as indi-
cative of ACC recurrence (sensitivity 56%, CI 39–72%); 
in 6 of these patients, recurrence was also detected in 
samples that preceded the first abnormal imaging. 
Applying the same diagnostic cut-off, 79% of samples 
provided by patients in the “non-recurred” cohort were 
correctly identified as non-recurred (false positive rate 
21% [95% CI 16%–27%]).
Figure 4. Assessment of longitudinally collected urine steroid profiling results by 3 expert clinicians (C1–C3). (A+B) Clinician assessment in the 32 
patients who developed disease recurrence, grouped according to whether they had provided preoperative urine samples (n = 13) or not (n = 19) 
(A) or whether they had adjuvant mitotane treatment at the time of recurrence (n = 12) or not (n = 20) (B). (C) Clinician assessment of urine 
profiles from 31 patients who remained disease-free for at least three years post-operatively and provided at least two post-operative samples. (D) 
Time interval between the detection of recurrent adrenocortical carcinoma by imaging and the earliest detection by clinician assessment of urine 
steroid profiles. Each point corresponds to a single urine sample; no patient is represented by more than one sample. Negative values indicate that 
biochemical detection preceded radiological detection.
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High-volume recurrences were more likely to 
be detected by the random forest classifier (sensi-
tivity 60% [95% CI 36%–80%] vs. 42% [95% CI 
19%–68%] in low-volume recurrences). However, 
detection was not affected by mitotane treatment 
(sensitivity 55% [95% CI 34%–74%] in mitotane-
treated patients vs. 58% [95% CI 32%–81%] in pa-
tients not treated with mitotane). Interestingly, in 11 
of 18 successfully diagnosed recurred patients, recur-
rence had also been unanimously detected by all 3 
assessing clinicians and in 16 of 18 by at least 2 dif-
ferent clinicians.
The machine learning analysis determined the 
11-deoxycortisol metabolite THS as the single most 
important steroid metabolite in differentiating post-
recurrence urine samples from samples provided by 
non-recurred patients, followed by the mineralocor-
ticoid precursor metabolite tetrahydrocorticosterone, 
the pregnenolone metabolite pregnenediol and the an-
drogen metabolite etiocholanolone (Fig. 5B).
Discussion
In this study, we explored the utility of urinary steroid pro-
filing as a novel diagnostic tool for recurrence detection in 
patients with microscopically complete (R0) resection of 
ACC. Results show that analysis of the steroid profiling data 
by a machine learning–based algorithm represents a highly 
promising noninvasive and radiation-free tool. Once valid-
ated prospectively, this would be a useful addition to the cur-
rent imaging-focused follow-up protocols, expediting scans 
in patients with suspicious biochemistry and informing dis-
cussions in cases with ambiguous imaging results.
Urinary steroid profiling in conjunction with machine 
learning-based data analysis, also termed urine steroid 
metabolomics, has already yielded highly promising 
results in several retrospective studies in patients with 
primary adrenal masses, where it was employed to dif-
ferentiate ACCs from benign adrenal tumors (15, 16). In 
the distinct clinical setting of postoperative patient sur-
veillance after resection of ACC, the use of urine steroid 
profiling has only been reported in a few cases (25, 26), 
but has never been systematically investigated.
In the present study, we studied 135 adult pa-
tients with microscopically complete R0 resection of 
ACC recruited from 14 centers associated with the 
European Network for the Study of Adrenal Tumors 
(ENSAT). Of the 81 patients who completed 3 years 
of postoperative surveillance, 42 (52%) recurred, a 
rate that is similar to previous retrospective studies 
(19, 27), which suggests that our patient cohort is 
representative of ACC patients routinely seen in clin-
ical practice.
An important finding of our study is that there were 
substantial similarities between the steroid profiles 
of recurrent ACCs and their respective steroid pro-
files collected preoperatively, with the primary tumor 
in situ. Indeed, half of all recurrent ACCs shared 4 or 
5 of their “top 6” most elevated steroid metabolites 
with their primary tumor of origin. Most of the “ma-
lignant steroid biomarkers” that were identified in our 
2011 study on primary adrenal tumors (15) were also 
highly relevant in the context of recurrent disease, com-
prising the “top 6” increased metabolites detected in 
urines collected from patients with ACC recurrences. 
Figure 5. Machine learning-based analysis of the urine steroid profile 
results. (A) Receiver operating characteristics curve analysis of the 
performance of random forest classification in distinguishing post-
recurrence samples from samples provided by non-recurred patients. 
The performance of the three clinician assessors (C1–C3) has also 
been plotted for comparison. Steroid numbers correspond to Table 
1. (B) Random forest assessment of the relative importance of the 19 
steroid metabolites in distinguishing post-recurrence samples (n = 32) 
from postoperative samples provided by non-recurred patients 
(n = 39), quantifying the significance of each single steroid marker 
for the detection of adrenocortical carcinoma recurrence, with all 
significances adding up to the sum of 1.
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Consequently, expert clinicians had improved ability to 
detect recurrence if a preoperative urine steroid profile 
was available. This emphasizes the importance of pre-
operative, baseline sample collection to facilitate per-
sonalized management in patients with ACC, a rare 
cancer in which baseline tissue and blood collection is 
increasingly becoming routine to support individual-
ized diagnosis and therapy (28).
We assessed the diagnostic potential of urinary steroid 
profiling as a recurrence surveillance tool using two ap-
proaches: (i) an “expert review” approach and (ii) auto-
matic recurrence detection by computational analysis of 
steroid data using a machine learning–based algorithm. 
On retrospective, blinded assessment of serial 24-hour 
urine collections, clinicians were able to detect recur-
rence by the time of its first radiological manifestation 
with high sensitivity in cases where a preoperative urine 
sample was available. In patients who were only able 
to contribute postoperative urine samples, the ability of 
clinicians to detect recurrence was substantially lower.
Adjuvant mitotane did not compromise the diag-
nostic performance of reviewing clinicians, despite the 
drug’s well documented ability to inhibit steroidogenesis 
(18). Mitotane interferes with adrenal steroidogenesis in 
a number of ways, including (i) overall suppression of 
steroidogenesis resulting in lower excretion values for all 
steroid metabolites, (ii) increased glucocorticoid break-
down by  induction of CYP3A4, necessitating high-dose 
hydrocortisone replacement; and (iii) 5α-reductase inhib-
ition, leading to a decrease in 5α-reduced steroids (18). 
Although mitotane appeared to blunt the magnitude of 
the increases in ACC-specific steroid biomarkers in re-
curred patients, it also suppressed the random sample-to-
sample variability, which can be diagnostically helpful. 
We systematically excluded glucocorticoid metabolites 
from the steroid analysis, as these would be comprom-
ised both by mitotane-induced changes in glucocorticoid 
metabolism and exogenous hydrocortisone replacement.
We applied a machine learning–based approach to 
the urinary steroid profiling data to detect recurrent 
ACC in an automated and defined fashion. The bio-
chemical complexity of steroidogenesis with multiple 
substrates, products, and pathways, in combination 
with the small underlying disease volumes in the setting 
of recurrent malignancy, render individual biomarkers 
diagnostically insufficient. Machine learning–based ap-
proaches are ideally suited to systematically evaluate 
the wealth of data provided by multisteroid profiling 
in an objective and reproducible fashion, as already 
demonstrated in the differential diagnosis of adrenal 
incidentalomas (15). Our classifier could distinguish re-
curred samples from samples provided by non-recurred 
patients with considerable accuracy. THS was the most 
important indicator of malignancy, reflecting the pat-
tern of inefficient steroidogenesis in ACC that emerged 
in previous studies on detection of ACC in patients with 
adrenal masses (15, 17, 29). Indeed, all but one of the 6 
steroids that were identified by random forest as most 
differentiating between recurrence and non-recurrence 
are contained in the previously described “malignant 
steroid fingerprint” in ACC (15). It should be noted 
that, unlike assessing clinicians, the computational clas-
sifier did not take into account the dynamic longitudinal 
changes in steroid metabolites in individual patients but 
judged every sample on its own.
To our knowledge, this is the first study systematically 
exploring the diagnostic potential of urine steroid pro-
filing in the postoperative monitoring of ACC patients. 
Strengths of our study include the large cohort size and 
the application of computational analysis to meet the de-
mands of the multivariable GC-MS steroid datasets. The 
limitations of our work pertain to the paucity of pre-
operative samples in the majority of patients, the variable 
frequency of postoperative sample collections and the fact 
that the machine learning classifier has not been validated 
on an additional data set. We also did not systematically 
compare the results of routine biochemical analysis of 
serum steroids to the 24-hour urine analysis by GC-MS; 
however, we previously demonstrated that routine serum 
biochemistry only identified abnormalities in 73% of 
ACC patients (n = 47), while urine steroid metabolomics 
by GC-MS found abnormalities in 95% (15).
On this background, and despite the generally small 
disease volume in the recurred patients, in comparison 
to patients presenting with a large primary tumors 
(15), our approach yielded very promising diagnostic 
results. Our data indicate that availability of a pre-
operative urine and, thus, of the preoperative “steroid 
fingerprint” considerably improves the likelihood of 
recurrence  detection and, therefore, the preservation 
of a preoperative 24-hour urine sample should be rou-
tinely  considered, in addition to preservation of serum, 
plasma, and tissue, to facilitate precision medicine.
In conclusion, we demonstrated that urine steroid 
metabolomics, that is, the combination of mass spec-
trometry–based steroid profiling with machine learning–
based steroid data analysis, is superior to interpretation 
of steroid profile results by individual experts. Following 
potential further refinement of this algorithm, this diag-
nostic approach should be taken forward to be assessed 
against radiological disease detection in a prospective 
test validation study with systematic collection of pre- 
and postoperative urines in defined intervals. This will 
also allow for systematic comparison of serum and 
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24-hour urine steroid profiles and ideally utilize high-
throughput technology, such as liquid chromatography–
tandem mass  spectrometry or also, as recently published 
(30), high resolution accurate mass spectrometry, both 
assays highly suitable for rollout of urine steroid 
metabolomics into the routine clinical context.
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